Kyoung Lim Kim

US Patent:

6392053, May 21, 2002

Filed:

Dec 22, 2000

Appl. No.:

09/746059

Inventors:

Kyoung S. Kim - North Brunswick NJ
S. David Kimball - East Windsor NJ
Raj N. Misra - Hopewell NJ
Joseph E. Sundeen - Yardley PA
Rulin Zhao - Pennington NJ

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07D41712

US Classification:

548185

Abstract:

The present invention relates to new, efficient processes for the preparation of 5-(2-oxazolylalkylthio)-2-arylacetylaminothiazole compounds of formula I or a pharmaceutically acceptable salt thereof, wherein: R , R , R , R , R , R , R , R and R are each independently hydrogen, alkyl, aryl or heteroaryl; R , R , R and R are each independently hydrogen, alkyl, aryl, heteroaryl, halogen, hydroxy or alkoxy; and X is CH or N, which are novel, potent inhibitors of cyclin dependent kinases (cdks). The present invention also concerns a new process for the preparation of formylarylacetates and formylarylacetic acids.

US Patent:

6414156, Jul 2, 2002

Filed:

Dec 22, 2000

Appl. No.:

09/746060

Inventors:

Kyoung S. Kim - North Brunswick NJ
S. David Kimball - East Windsor NJ
Raj N. Misra - Hopewell NJ
Mark E. Salvati - Lawrenceville NJ
Joseph E. Sundeen - Yardley PA
Rulin Zhao - Pennington NJ

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07D41714

US Classification:

546209, 548185

Abstract:

The present invention relates to new, efficient processes for the preparation of 5-(2-oxazolylalkylthio)-2-azacycloalkanoylaminothiazole compounds of formula I or a pharmaceutically acceptable salt thereof, wherein: R is alkyl, aryl or heteroaryl; R , R , R , R and R are each independently hydrogen, alkyl, aryl or heteroaryl; R and R are each independently hydrogen, alkyl, aryl, heteroaryl, halogen, hydroxy or alkoxy; R is hydrogen, alkyl, aryl, heteroaryl, CONR R , COR or COOR ; R , R , R and R are each independently hydrogen, alkyl or aryl; m equals 0 to 5; and n equals 0 to 5, which are novel, potent inhibitors of cyclin dependent kinases (cdks). The present invention further concerns new key intermediate compounds, a quaternary ammonium salt of formula IIIâ and a 2-oxazolylalkyl derivative of formula IX.

US Patent:

6521759, Feb 18, 2003

Filed:

Apr 20, 2001

Appl. No.:

09/839751

Inventors:

Kyoung S. Kim - North Brunswick NJ
S. David Kimball - East Windsor NJ
David B. Rawlins - Morrisville PA
Raj N. Misra - Hopewell NJ
Michael A. Poss - Lawrenceville NJ
Kevin R. Webster - Yardley PA
John T. Hunt - Princeton NJ
Wen-Ching Han - Newtown PA

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07D41712

US Classification:

548184

Abstract:

The present invention describes compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R , R , R , R , R , m and n are as defined in the specification. The compounds of formula I are protein kinase inhibitors and are useful in the treatment of proliferative diseases, for example, cancer, inflammation and arthritis. They may also be useful in the treatment of Alzheimers disease, chemotherapy-induced alopecia, and cardiovascular disease.

US Patent:

6613911, Sep 2, 2003

Filed:

Feb 5, 2002

Appl. No.:

10/067723

Inventors:

Kyoung S. Kim - North Brunswick NJ
S. David Kimball - East Windsor NJ
Raj N. Misra - Hopewell NJ
Joseph E. Sundeen - Yardley PA
Rulin Zhao - Pennington NJ

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07D41712

US Classification:

548185

Abstract:

The present invention relates to new, efficient processes for the preparation of 5-(2-oxazolylalkylthio)-2-arylacetylaminothiazole compounds of formula I: or a pharmnaceutically acceptable salt thereof, wherein: R , R , R , R , R , R , R , R and R are each independently hydrogen, alkyl, aryl or heteroaryl; R , R , R and R are each independently hydrogen, alkyl, aryl, heteroaryl, halogen, hydroxy or alkoxy; and X is CH or N, which are novel, potent inhibitors of cyclin dependent kinases (cdks). The present invention also concerns a new process for the preparation of formylarylacetates and formylarylacetic acids.

US Patent:

6639074, Oct 28, 2003

Filed:

Mar 18, 2002

Appl. No.:

10/100129

Inventors:

Kyoung S. Kim - North Brunswick NJ
S. David Kimball - East Windsor NJ
Raj N. Misra - Hopewell NJ
Mark E. Salvati - Lawrenceville NJ
Joseph E. Sundeen - Yardley PA
Rulin Zhao - Pennington NJ

Assignee:

Bristol Myers Squibb Company - Princeton NJ

International Classification:

C07D47100

US Classification:

546 63

Abstract:

The present invention relates to new, efficient processes for the preparation of 5-(2-oxazolylalkylthio)-2-azacycloalkanoylaminothiazole compounds of formula I or a pharmaceutically acceptable salt thereof, wherein: R is alkyl, aryl or heteroaryl; R , R , R , R and R are each independently hydrogen, alkyl, aryl or heteroaryl; R and R are each independently hydrogen, alkyl, aryl, heteroaryl, halogen, hydroxy or alkoxy; R is hydrogen, alkyl, aryl, heteroaryl, CONR R , COR or COOR ; R , R , R and R are each independently hydrogen, alkyl or aryl; m equals 0 to 5; and n equals 0 to 5, which are novel, potent inhibitors of cyclin dependent kinases (cdks). The present invention further concerns new key intermediate compounds, a quaternary ammonium salt of formula IIIâ and a 2-oxazolylalkyl derivative of formula IX.

US Patent:

6897321, May 24, 2005

Filed:

Aug 12, 2003

Appl. No.:

10/639272

Inventors:

Kyoung S. Kim - North Brunswick NJ, US
S. David Kimball - East Windsor NJ, US
Raj N. Misra - Hopewell NJ, US
Mark E. Salvati - Lawrenceville NJ, US
Joseph E. Sundeen - Yardley PA, US
Rulin Zhao - Pennington NJ, US

Assignee:

Briston Myers Squibb Company - Princeton NJ

International Classification:

C07D263/30

US Classification:

548235

Abstract:

The present invention relates to new, efficient processes for the preparation of 5-(-2-oxyazolylalkylthio)-2-azacycloalkanoylaminothiazole compounds of formula I or a pharmaceutically acceptable salt thereof, wherein:.

US Patent:

7022850, Apr 4, 2006

Filed:

May 18, 2004

Appl. No.:

10/848089

Inventors:

Kyoung S. Kim - North Brunswick NJ, US
Songfeng Lu - Raritan NJ, US
Alvin Donald Crews - Voorhees NJ, US

Assignee:

Bristol-Myers Squibb Co. - Princeton NJ

International Classification:

C07D 498/04
C07D 513/04

US Classification:

544255, 544256

Abstract:

The present invention is directed to dihydropyrimidones having formula I or II and methods of using them to induce mitotic arrest, thereby making them useful as anti-cancer agents and other diseases that can be treated by inducing mitotic arrest.

US Patent:

7348325, Mar 25, 2008

Filed:

Nov 28, 2006

Appl. No.:

11/605168

Inventors:

Kyoung S. Kim - North Brunswick NJ, US
Robert M. Borzilleri - New Hope PA, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07D 487/04
C07D 471/04
C07D 401/12
C07D 403/12
A61K 31/53
A61K 31/4427
A61P 35/00
A61K 31/506
A61K 31/519

US Classification:

514243, 544183

Abstract:

In general, the instant invention comprises compounds having Formulae I and II:.